Not Signed In - Hepatitis B - Metabasis Comments On Positive 48 Week HBV Data From Pradefovir Mesylate Phase 2
Thu, 16 Mar 2006 11:00 PM EST
... Metabasis Therapeutics Inc.(Nasdaq: MBRX) commented today on the 48 week results from a Phase 2 study ofpradefovir, an oral anti-viral product candidate it discovered andsubsequently licensed to Valeant Pharmaceuticals International. Valeant isevaluating the safety and efficacy of pradefovir for the treatment ofcompensated chronic hepatitis B... click link for more info. ...
Related Topics
- Data & Statistics
- Hepatitis C
- Data Analysis
- Hepatitis B
- National Data
- Lamivudine
- Hepatitis A
- Fetal Development
- Hepatitis
- Hepatitis A and Hepatitis B Vaccine
- Hepatitis A Vaccine
- Hepatitis B Vaccine
- Autoimmune Hepatitis
- Pregnancy
- Mining
- Gemifloxacin mesylate
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Tb
- National Women's Health Week
email this page
print this page
bookmark this page
feedback on this page
